APM
Avidity Partners Management Portfolio holdings
AUM
$499M
This Quarter Return
+7.36%
1 Year Return
+3.47%
3 Year Return
+181.12%
5 Year Return
+409%
10 Year Return
–
AUM
$499M
AUM Growth
+$499M
(+2.9%)
Cap. Flow
+$5.91M
Cap. Flow
% of AUM
1.19%
Top 10 Holdings %
Top 10 Hldgs %
49.06%
Holding
80
New
17
Increased
18
Reduced
13
Closed
25
Top Buys
| 1 |
HNGE
Hinge Health, Inc.
HNGE
|
$16.7M |
| 2 |
Intuitive Surgical
ISRG
|
$14.7M |
| 3 |
Natera
NTRA
|
$13.5M |
| 4 |
CG Oncology
CGON
|
$13.5M |
| 5 |
Genmab
GMAB
|
$13.4M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$16.1M |
| 2 |
Glaukos
GKOS
|
$13.2M |
| 3 |
Humana
HUM
|
$13.1M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$9.93M |
| 5 |
Neurocrine Biosciences
NBIX
|
$9.48M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CG Oncology
CGON
$2.04B
| $39M | 7.77% | 1,499,942 +519,000 | +53% | +$13.5M |
|
2
Boston Scientific
BSX
$156B
| $34.6M | 6.89% | 321,800 -14,200 | -4% | -$1.53M |
|
|
3
Natera
NTRA
$23.1B
| $33.7M | 6.71% | 199,300 +80,100 | +67% | +$13.5M |
|
4
Dianthus Therapeutics
DNTH
$759M
| $32.5M | 6.47% | 1,742,902 +22,000 | +1% | +$410K |
|
5
Exact Sciences
EXAS
$8.98B
| $18.9M | 3.76% | 355,000 +2,000 | +0.6% | +$106K |
|
6
Tenet Healthcare
THC
$16.3B
| $18.7M | 3.72% | 106,000 +34,000 | +47% | +$5.98M |
|
7
DexCom
DXCM
$29.5B
| $18.4M | 3.66% | 210,500 +30,500 | +17% | +$2.66M |
|
8
Danaher
DHR
$147B
| $17.7M | 3.53% | 89,700 +45,200 | +102% | +$8.93M |
|
|
HNGE
9
Hinge Health, Inc.
HNGE
$4.4B
| $16.7M | 3.32% | +322,344 | New | +$16.7M |
|
|
10
Intuitive Surgical
ISRG
$170B
| $14.7M | 2.93% | +27,100 | New | +$14.7M |
|
|
11
Genmab
GMAB
$15.3B
| $13.4M | 2.68% | +650,000 | New | +$13.4M |
|
12
Repligen
RGEN
$6.88B
| $13.2M | 2.64% | +106,500 | New | +$13.2M |
|
13
Thermo Fisher Scientific
TMO
$186B
| $12M | 2.39% | 29,600 +14,100 | +91% | +$5.72M |
|
14
Teva Pharmaceuticals
TEVA
$21.1B
| $11.6M | 2.3% | 689,500 +208,500 | +43% | +$3.49M |
|
|
JBIO
15
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $11.3M | 2.24% | +1,127,186 | New | +$11.3M |
|
16
Phathom Pharmaceuticals
PHAT
$864M
| $10.2M | 2.03% | 1,064,500 +264,500 | +33% | +$2.54M |
|
17
UnitedHealth
UNH
$281B
| $9.98M | 1.99% | 32,000 -18,500 | -37% | -$5.77M |
|
18
McKesson
MCK
$85.4B
| $9.89M | 1.97% | +13,500 | New | +$9.89M |
|
19
Axsome Therapeutics
AXSM
$6.05B
| $9.86M | 1.97% | 94,500 +17,500 | +23% | +$1.83M |
|
20
Cencora
COR
$56.5B
| $9.84M | 1.96% | 32,800 -6,500 | -17% | -$1.95M |
|
21
HealthEquity
HQY
$7.72B
| $9.64M | 1.92% | 92,000 +14,000 | +18% | +$1.47M |
|
22
Encompass Health
EHC
$12.3B
| $9.07M | 1.81% | +74,000 | New | +$9.07M |
|
23
Revolution Medicines
RVMD
$7.1B
| $8.41M | 1.68% | 228,600 +15,600 | +7% | +$574K |
|
24
Akero Therapeutics
AKRO
$3.74B
| $7.15M | 1.42% | 134,000 +77,000 | +135% | +$4.11M |
|
|
OMDA
25
Omada Health, Inc. Common Stock
OMDA
$1.36B
| $7.15M | 1.42% | +390,600 | New | +$7.15M |
|